PPARG Polymorphisms Are Associated with Unexplained Mild Vision Loss in Patients with Type 2 Diabetes Mellitus

Tao Li, Xian Xu, Yi Xu, Peiyao Jin, Jianhua Chen, Yongyong Shi, Haidong ZouJournal of Ophthalmology 2019 · DOI

TL;DR

This study investigates the genetic underpinnings of unexplained mild vision loss (UMVI) in Type 2 Diabetes Mellitus (T2DM) patients. Researchers found specific variations in the PPARG gene are significantly associated with an increased risk of UMVI, suggesting a genetic predisposition that may lead to early photoreceptor cell dysfunction.

What Problem Does This Paper Address?

Type 2 Diabetes Mellitus (T2DM) is a widespread metabolic disorder with numerous complications, including ocular issues. While severe visual impairment and blindness in T2DM patients have been extensively studied, mild visual impairment (defined as best-corrected visual acuity (BCVA) between 20/25 and 20/63) that lacks a clear identifiable cause (unexplained mild visual impairment or UMVI) has received less attention. This gap is problematic because UMVI can indicate early stages of retinal damage and may precede more severe vision loss, yet its underlying mechanisms, particularly genetic factors, remain largely unknown. This paper aims to shed light on the genetic susceptibility to UMVI in T2DM patients by examining polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma (PPARG) gene.

Methods

The study employed a case-control design, comparing T2DM patients with UMVI (cases) to T2DM patients with normal vision (controls).

  • Patient Selection: 135 T2DM patients with UMVI and 133 T2DM patients with normal vision (BCVA ≥ 20/25 in both eyes) were recruited. UMVI was defined as BCVA < 20/25 and ≥ 20/63 in both eyes, with no other identifiable causes of visual impairment. Exclusion criteria included other eye diseases or systemic conditions that could affect vision.
  • SNP Selection: Four specific single-nucleotide polymorphisms (SNPs) in the PPARG gene (rs1801282, rs3856806, rs709158, and rs10865710) were chosen based on their known associations with metabolic disorders and lipoprotein metabolism.
  • Genotyping: DNA was extracted from blood samples, and genotyping of the selected PPARG SNPs was performed using Fluidigm SNP genotyping technology. This method involves amplifying target regions and then using allele-specific primers to determine the genotype.
  • Statistical Analysis: Standard statistical tests (Student's t-test, chi-square test, Fisher's exact test) were used to compare demographic and clinical characteristics. Hardy-Weinberg equilibrium (HWE) was assessed for genotype frequencies. Allelic and genotypic frequencies were compared between UMVI and normal vision groups. Odds ratios (OR) and 95% confidence intervals (CI) were calculated to assess the association between SNPs and UMVI. Pairwise linkage disequilibrium (LD) analysis was conducted using HAPLOVIEW.

Datasets

The study utilized data from 135 T2DM patients with UMVI and 133 T2DM patients with normal vision from the Shanghai Xinjing community. No new benchmark datasets were introduced.

Key Insights and Ideas

  • PPARG Gene as a Susceptibility Factor: The study strongly implicates specific variations within the PPARG gene as a significant genetic factor contributing to unexplained mild vision loss in T2DM patients.
  • Mechanism of Action: The identified PPARG polymorphisms (rs10865710 and rs3856806) are hypothesized to affect PPARG transcription, leading to altered protein levels. This, in turn, may influence the retina's response to oxidative stress and hyperglycemia, ultimately causing early dysfunction of photoreceptor cells.
  • Potential for Therapeutic Intervention: The findings suggest that PPARG agonists, such as pioglitazone, which are known to have protective effects on retinal cells, could potentially be used to prevent or manage the progression of visual impairment in T2DM patients.

Key Results

  • Significant Associations: Two specific PPARG SNPs showed a strong association with UMVI:
  • rs10865710: The GC genotype was significantly more frequent in the UMVI group, increasing the risk of UMVI by approximately 8.94-fold. Conversely, the CC genotype appeared protective.
  • rs3856806: The TT genotype was strongly associated with UMVI, conferring a more than 3-fold increased risk. The CC genotype was found to be protective.
  • Linkage Disequilibrium: A linkage disequilibrium block of 39 kb was identified, including the four studied SNPs, with rs10865710 and rs1801282 being in complete LD.
  • Demographic Similarities: Apart from waistline and hipline, the UMVI and normal vision groups showed no significant differences in demographic or clinical characteristics like age, diabetes duration, or HbA1c levels, suggesting that the observed vision loss is not solely attributable to these factors.

Limitations and Future Work

  • Limitations:
    • The study was a single-center study based on the Chinese Han population, limiting generalizability to other ethnic groups.
  • A relatively small number of subjects were included.
  • Only four SNPs of the PPARG gene were analyzed; a more comprehensive sequencing of the PPARG gene is recommended.
  • Future Work:
    • Larger, multi-center studies are needed to confirm these findings and improve generalizability.
  • Further investigation into a wider range of PPARG SNPs and other relevant genes is warranted to fully elucidate the genetic architecture of UMVI in T2DM.
  • Exploring the functional impact of these specific polymorphisms on PPARG transcription and protein function would provide deeper mechanistic insights.

Summary updated

Abstract

Susceptibilities of PPARG variants may lead to differences in PPARG transcription, result in early function loss of retinal photoreceptor cells, and eventually cause UMVI.
BibTeX
@article{li2019pparg,
  author = {Tao Li and Xian Xu and Yi Xu and Peiyao Jin and Jianhua Chen and Yongyong Shi and Haidong Zou},
  title = {{PPARG Polymorphisms Are Associated with Unexplained Mild Vision Loss in Patients with Type 2 Diabetes Mellitus}},
  journal = {Journal of Ophthalmology},
  year = {2019},
  doi = {10.1155/2019/5284867},
}
Figure